Background: L-Dopa decarboxylase (DDC) expression has been implicated in the biochemistry of several human cancers. Docetaxel and Mitoxantrone are two widely used anticancer agents. Docetaxel is a semi-synthetic analogue of Paclitaxel, an extract from the bark of the rare Pacific yew tree Taxus brevifolia, and Mitoxantrone is an anthracenedione anticancer agent.
Objective: The purpose of the present study was to investigate the effect of chemotherapeutic agents on the expression of human DDC in human prostate and human breast cancer cell lines. Furthermore, the study focused on the effect of chemotherapeutics - particularly Docetaxel and Mitoxantrone – on the viability of mammalian cells expressing human DDC protein isoforms.
Methods: We investigated the effect of Docetaxel and Mitoxantrone on the expression of DDC in DU- 145 (androgen-independent prostate cancer cell line) and MCF-7 (human breast adenocarcinoma cell line). In order to gain insight into the effect of DDC on cell viability following chemotherapeutic agent treatment, we investigated the cytotoxicity and apoptosis levels on CHO cells expressing different human DDC protein isoforms.
Results: Our obtained data indicated that exposure of DU-145 and MCF-7 cells to Docetaxel and Mitoxantrone enhances the expression of neural type DDC mRNA isoforms. Interestingly, DDC protein levels were not affected, despite the cytotoxic events elicited by the chemotherapeutic agent treatment. Moreover, expression of DDC and its alternative protein isoforms, appear to enhance the cytotoxic and apoptotic events conferred by exposure to Docetaxel and Mitoxantrone.
Conclusion: This study suggests the possible involvement of DDC expression in Docetaxel and Mitoxantrone- induced cytotoxicity and apoptosis.
Keywords: DDC, alternative isoforms, prostate cancer, breast cancer, cell death, apoptosis.
The History, Mechanism and Clinical Use of Oral 5-Fluorouracil Derivative Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Aurones as New Porcine Pancreatic α-Amylase Inhibitors
Letters in Drug Design & Discovery PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Using a Machine-Learning Approach to Predict Discontinuous Antibody-Specific B-Cell Epitopes
Current Bioinformatics Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Osteopontin: An Effector and an Effect of Tumor Metastasis
Current Molecular Medicine Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Optimize Administration Protocol of Capecitabine Plus Docetaxel Combination in Metastatic Breast Cancer Patients
Current Topics in Medicinal Chemistry EGFR Mutation Testing in Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
Current Drug Targets Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Meet our Associate Editorial Board Member
Current Cancer Therapy Reviews Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB
Anti-Cancer Agents in Medicinal Chemistry Sub Cellular Organelles-targeting Photo Dynamic Therapy (PDT)
Mini-Reviews in Organic Chemistry